Latest news
New BTK Inhibitor Approved for Urticaria - MedscapeMedscape · Fri, 07 Aug 2026 14:53:14 GMTComparing CV Safety and Exploratory Bleeding Outcomes of BTK Inhibitors in Mantle Cell Lymphoma - The American Journal of Managed Care® (AJMC®)The American Journal of Managed Care® (AJMC®) · Wed, 05 Aug 2026 20:44:48 GMTCombining BTK and BCL2 Inhibitors in Mantle Cell Lymphoma: Eyre Weighs in on Where the Field Goes Next - The American Journal of Managed Care® (AJMC®)The American Journal of Managed Care® (AJMC®) · Wed, 05 Aug 2026 20:31:11 GMTBTK Inhibitors in Chronic Lymphocytic Leukemia: Current Practice and Future Perspectives - OncodailyOncodaily · Mon, 03 Aug 2026 00:05:55 GMTSymposium | BTK inhibitors in practice: Treatment selection and emerging clinical evidence - lymphomahub.comlymphomahub.com · Fri, 31 Jul 2026 11:14:32 GMTProcessa acquires CNS-penetrant BTK inhibitor VT-7208 with USD 200m financing for three Phase II programs - AllSciAllSci · Thu, 30 Jul 2026 16:13:05 GMTProcessa acquires Vidya and its BTK inhibitor - The Pharma LetterThe Pharma Letter · Thu, 30 Jul 2026 12:02:43 GMTProcessa snaps up Vidya and its BTK inhibitor, raises $200M for mid-stage trials - FirstWord PHARMAFirstWord PHARMA · Wed, 29 Jul 2026 21:06:26 GMT